


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of formula I



in which

R^1 is Hal, NO_2 , CF_3 , $COOH$, $COOR$ or H ,
 R^2 is R , Hal, CN , NO_2 , NHR , NRR , $NHCOR$, $NHSO_2R$, OR , $CO-R$, $CO-NHR$, CF_3 ,
 OCF_3 , SCF_3 , SO_3R , SO_2R , SO_2NR , SR , $COOH$ or $COOR$,
 R^3 is H , Hal or $CO-NHR$,
 R is H or unsubstituted or mono-, di-, tri- or tetra- R^4 -substituted A , Ar , Het , $(CH_2)_qHet$ or $(CH_2)_qAr$,
 A is unbranched, branched or cyclic alkyl having 1-14 C atoms, in which one or two CH_2 groups are each optionally replaced by O , S , or $-CH=CH-$ and/or 1-7 H atoms are each optionally replaced by F or Cl ,
 Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by A , Hal, OH , OA , CN , NO_2 , NH_2 , NHA , NA_2 , $NHCOA$, SCF_3 , SO_2A , $COOH$, $COOA$, $CONH_2$, $CONHA$, $CONA_2$, $NHSO_2A$, SO_2NH_2 , SO_2NHA , SO_2NA_2 , CHO or COA ,
 Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by carbonyl oxygen, Hal, A , $-(CH_2)_b-Ar$, $-(CH_2)_b-cycloalkyl$, OH , OA , NH_2 ,

NHA, NA₂, NO₂, CN, COOH, COOA, CONH₂, CONHA, CONA₂, NHCOA,
NHCONH₂, NHSO₂A, CHO, COA, SO₂NH₂ and/or S(O)_gA,

Hal is F, Cl, Br or I,

R⁴ is Hal, OH, CN, NO₂, CF₃, OCF₃, SCF₃, SO₂A or OA,

X is O, S, SO₂NH or NH,

(Y) is phenyl or a monocyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms,

b is 0, 1, 2, 3 or 4,

g is 0, 1 or 2,

n, m, p, q are each, independently of one another, 1, 2, 3, or 4,

or a pharmaceutically acceptable salt, or stereoisomer thereof, including mixtures of stereoisomers in all ratios.

2. (Cancelled):

3. (Previously Presented): A compound according to Claim 1, in which R² is H.

4. (Cancelled):

5. (Previously Presented): A compound according to claim 1, in which (Y) is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl.

6. (Withdrawn): A compound according to Claim 1, in which

R² is H,

(Y) is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl,

X is O, S, SO₂NH or NH,

n, p, are each, independently of one another, 1, 2, 3 or 4,

m is 1.

7. (Previously Presented): A compound selected from:


benzoxazol-2-yl-[4-(pyridin-4-yloxy)phenyl]amine,

benzoxazol-2-yl-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
N-benzoxazol-2-yl-N'-pyridin-4-ylbenzene-1,4-diamine,
2-[4-(pyridin-4-ylsulfanyl)phenylamino]benzoxazole-5-carboxylic acid,
2-[4-(pyridin-4-yloxy)phenylamino]benzoxazole-6-carboxylic acid,
2-[4-(pyridin-4-ylsulfanyl)phenylamino]benzoxazole-6-carboxylic acid,
methyl 2-[4-(pyridin-4-ylamino)phenylamino]benzoxazole-6-carboxylate,
(5-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
(5-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
N-(5-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
(6-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
(6-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
N-(6-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
(5-chloro-7-nitrobenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,
(5-chloro-7-nitrobenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]amine,
N-(5-chloro-7-nitrobenzoxazol-2-yl)-N'-pyridin-4-ylbenzene-1,4-diamine,
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(pyridin-4-yloxy)phenyl]-
amine,
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(pyridin-4-ylsulfanyl)phenyl]-
amine,
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(4-fluorophenylsulfanyl)-
phenyl]amine,
N-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenyl]-4-fluoro-
benzenesulfonamide,
[4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl]-(7-bromo-5-trifluoro-
methylbenzoxazol-2-yl)amine,
N-methyl-4-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenoxy]-
pyridine-2-carboxamide,
N-methyl-4-[4-(bromotrifluoromethylbenzoxazol-2-ylamino)phenylsulfanyl]-
pyridine-2-carboxamide, and
(7-bromo-5-trifluoromethylbenzoxazol-2-yl)-[4-(2,4-difluorophenylsulfanyl)-
phenyl]amine,


and pharmaceutically acceptable salts, and stereoisomers thereof, including mixtures of stereoisomers in all ratios.

8. (Previously Presented): A process for preparation of a compound according to claim 1, said process comprising:

reacting a compound of formula II



with a compound of formula III



9. (Previously Presented): A pharmaceutical composition comprising at least one compound according to claim 1 and one or more excipients and/or adjuvants.

10. (Previously Presented): A pharmaceutical composition comprising at least one compound according to claim 1, and at least one further medicament active ingredient.

11. (Previously Presented): A kit consisting of separate packs of
a) an effective amount of a compound according to claim 1, and
b) an effective amount of a further medicament active ingredient.

12. (Cancelled):

13. (Cancelled):

14. (Withdrawn): A method of treating a patient suffering from a cancerous disease comprising administering to said patient an effective amount of a compound according to claim 1.

15. (Withdrawn): A method of treating a patient suffering from a disease that is caused, mediated and/or propagated by kinases and/or by kinase-mediated signal transduction, comprising administering to said patient an effective amount of a compound according to claim 1.

16. (Withdrawn): A method according to Claim 15, where the kinases are selected from tyrosine kinases.

17. (Withdrawn): A method according to Claim 16, where the tyrosine kinases are TIE-2 or VEGFR.

18. (Withdrawn): A method according to Claim 15, where the kinases are selected from Raf kinases.

19 (Withdrawn): A method according to Claim 18, where the Raf kinases are A-Raf, B-Raf or Raf-1.

20. (Withdrawn): A method for treating a solid tumor in a patient comprising administering to said patient an effective amount of a compound according to claim 1.

21. (Withdrawn): A method according to Claim 20, where the solid tumour is selected from brain tumour, tumour of the urogenital tract, tumour of the lymphatic system, stomach tumour, laryngeal tumour, and lung tumour.

22. (Withdrawn): A method according to Claim 20, where the solid tumour is selected from monocytic leukaemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas, and breast carcinoma.

23. (Withdrawn): A method for treating a patient suffering from a disease that is caused, mediated and/or propagated by angiogenesis, comprising administering to said patient an effective amount of a compound according to claim 1.

24. (Withdrawn): A method for treating a patient suffering from retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and/or an inflammatory disease, comprising administering to said patient an effective amount of a compound according to claim 1.

25. (Withdrawn): A method for treating a patient suffering from osteosarcoma, osteoarthritis, or rickets, comprising administering to said patient an effective amount of a compound according to claim 1.

26. (Withdrawn): A method for treating a patient suffering from psoriasis, rheumatoid arthritis, contact dermatitis, delayed hypersensitivity reaction, inflammation, endometriosis, scarring, benign prostatic hyperplasia, an immunological disease, an autoimmune disease, or an immunodeficiency disease, comprising administering to said patient an effective amount of a compound according to claim 1.

27. (Withdrawn): A method for treating a patient suffering from brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia, or and acute leukaemia, comprising administering to said patient an effective amount of a compound according to claim 1.

28. (Withdrawn): A method according to claim 1, wherein said effective amount

of a compound according to claim 1 is administered in combination with a compound selected from 1) oestrogen receptor modulators, 2) androgen receptor modulators, 3) retinoid receptor modulators, 4) cytotoxic agents, 5) antiproliferative agents, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors 9) reverse transcriptase inhibitors, 10) growth factor receptor inhibitors, and 11) angiogenesis inhibitors.

29. (Withdrawn): A method according to claim 1, wherein said effective amount of a compound according to claim 1 is administered in combination with

a compound selected from 1) oestrogen receptor modulators, 2) androgen receptor modulators, 3) retinoid receptor modulators, 4) cytotoxic agents, 5) antiproliferative agents, 6) prenyl-protein transferase inhibitors, 7) HMG-CoA reductase inhibitors, 8) HIV protease inhibitors 9) reverse transcriptase inhibitors, 10) growth factor receptor inhibitors, and 11) angiogenesis inhibitors, and

radiotherapy.

30. (Previously Presented): A compound according to claim 1, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl, decyl, trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

31. (Previously Presented): A compound according to claim 30, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl.

32. (Previously Presented): A compound according to claim 30, wherein A is alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which one or two CH₂ groups are each optionally replaced by O, S, or by -CH=CH-, and 1-7 H are each optionally replaced by F or Cl.

33. (Previously Presented): A compound according to claim 30, wherein A is

methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl, or 1,1,1-trifluoroethyl.

34. (Previously Presented): A compound according to claim 1, wherein Ar is phenyl, naphthyl or biphenyl, which in each case is mono-, di- or trisubstituted by substituents selected from A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and aminocarbonyl.

35. (Previously Presented): A compound according to claim 1, wherein Het is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-iso-thiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, furthermore preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, or 2,1,3-benzoxadiazol-5-yl, which in each case is unsubstituted or mono-, di- or trisubstituted by substituents selected from carbonyl oxygen, F, Cl, Br, methyl, ethyl, propyl, phenyl, benzyl, -CH₂-cyclohexyl, hydroxyl, methoxy, ethoxy, amino, methylamino, dimethylamino, nitro, cyano, carboxyl, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, acetamino, ureido, methylsulfonylamino, formyl, acetyl, aminosulfonyl, and methylsulfonyl, or

Het is 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, furthermore preferably 2,3-methylenedioxophenyl, 3,4-methylenedioxophenyl, 2,3-ethylenedioxophenyl, 3,4-ethylenedioxophenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl, 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl, 2-hydroxy-6-oxopiperazin-1-yl, 2-methoxy-6-oxopiperazin-1-yl, or 2-azabicyclo[2.2.2]octan-3-on-2-yl.

36. (Previously Presented): A compound according to claim 1, wherein  is phenyl, pyridyl or pyrimidinyl.

37. (Previously Presented): A compound according to claim 35, wherein A is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, linear or branched heptyl, octyl, nonyl, decyl, trifluoromethyl, pentafluoroethyl, 1,1,1-trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; and

Ar is phenyl, naphthyl or biphenyl, which in each case is mono-, di- or trisubstituted by substituents selected from A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy,

ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, benzyloxy, sulfonamido, methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxyl, methoxycarbonyl, ethoxycarbonyl, and aminocarbonyl.

38. (Previously Presented): A compound according to Claim 1, in which

R^1 is Hal, NO_2 , CF_3 , COOH, COOR or H,

R^2 is H,

Y is phenyl, furyl, thienyl, pyrrolyl, imidazolyl, pyridyl or pyrimidinyl, and

X is O, S, SO_2NH or NH.